Optimization of the auxiliary ligand shell of Cobalt(III)(8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs.
A potential approach for activating prodrugs in hypoxic regions of tumors is to use ionizing radiation, rather than bioreductive enzymes, to effect reduction. This study investigates radiolytic release of 8-hydroxyquinoline (8-HQ), as a model for hydroxyaza-chloromethylbenzindoline DNA minor groove alkylators, from Co(III) complexes under hypoxia. 8-HQ release, measured by HPLC, showed higher efficiency (one-electron stoichiometry) when the auxiliary ligand was a tetraazamacrocycle [e.g. 1,4,7,10-tetraazacyclododecane (cyclen)] rather than a triazamacrocycle [1,4,7-triazacyclononane (TACN)]. These complexes differ from the bioreductive cobalt complex SN 24771 in that their reduction provides stable cobalt-containing products rather than free (aquated) Co(2+). Radiolytic release of 8-HQ from Co(cyclen)(8-HQ) and Co(TACN)(CN)(8-HQ) was also demonstrated in deoxygenated human plasma, selectively in the absence of oxygen, again with higher efficiency for the cyclen system. The cobalt complexes were >1000-fold less potent than free 8-HQ as inhibitors of cell proliferation and were metabolically stable in aerobic and hypoxic cell cultures. Investigation of cell uptake of total cobalt, by inductively coupled plasma mass spectrometry, showed that these complexes enter cells but do not accumulate to the high concentrations seen with SN 24771. The results demonstrate the feasibility of masking the cytotoxicity of hydroxyquinoline-based cytotoxins as Co(III) complexes and demonstrate the utility of cyclen-based auxiliary ligands for optimizing radiolytic activation of these novel prodrugs under hypoxia.
Ahn
G-One
GO
Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand.
Ware
David C
DC
Denny
William A
WA
Wilson
William R
WR
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000528:radiation effects; D016466:CHO Cells; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology*; D015687:Cell Hypoxia / Q000187:drug effects* / Q000528:radiation effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D003035:Cobalt / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000528:radiation effects; D006224:Cricetinae; D003412:Cricetulus; D004307:Dose-Response Relationship, Radiation; D016503:Drug Delivery Systems / Q000379:methods; D015195:Drug Design; D006801:Humans; D008024:Ligands; D051379:Mice; D015125:Oxyquinoline / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics* / Q000528:radiation effects*; D011355:Prodrugs / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics* / Q000528:radiation effects*
D000970:Antineoplastic Agents; D008024:Ligands; D011355:Prodrugs; D003035:Cobalt; D015125:Oxyquinoline